RxDoctor Payments Data

Roy Howard, PA

Medical · Anchorage, AKNPI 1689667586

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.6% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 48.7% of the total. Reporting peaked in 2021 at $508 and has fallen 89.1% since, to $56 in 2025.

$1,634in general payments, 2019–2025

Across 88 payments — averaging $18.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$795
  • LEO Pharma Inc.$140
  • Pfizer$117
  • Arcutis Biotherapeutics, Inc.$106
  • Sanofi$78
  • Sanofi-aventis U.S. LLC$72
  • plus $325 from 8 others

What the payments were for

  • Food & beverage$1,56296%
  • Education$724%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,634 in reported general payments places this provider in the 70th percentile of 140 medical providers in Alaska.

See all medical providers in Alaska

Medicare billing

Part B allowed, 2024
$106,181
Medicare patients
524
Services billed
1,089

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab17$94,719
ZoryveRoflumilast30$24,593
Calcipotriene34$10,274
Tretinoin69$4,319
Imiquimod205$3,531
Clobetasol Propionate71$2,488
Ivermectin15$2,485
Doxycycline Hyclate48$2,088
Azelaic Acid24$1,497
ValacyclovirValacyclovir Hcl41$1,444
Finasteride117$1,369
Acyclovir17$1,249
Fluorouracil21$1,078
Minoxidil89$963
Fluocinonide25$651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Arcutis Biotherapeutics, Inc.Zoryve$106$24,59330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 140 medical providers in Alaska.

Other medical in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →